Bioventures Ltd Novartis Sells 12,114 Shares of Ra Pharmctl Inc (RARX) Stock

Ra Pharmctl Inc (NASDAQ:RARX) major shareholder Bioventures Ltd Novartis sold 12,114 shares of the stock in a transaction on Wednesday, June 7th. The shares were sold at an average price of $22.63, for a total value of $274,139.82. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Large shareholders that own at least 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Bioventures Ltd Novartis also recently made the following trade(s):

  • On Monday, June 5th, Bioventures Ltd Novartis sold 19,647 shares of Ra Pharmctl stock. The shares were sold at an average price of $23.38, for a total value of $459,346.86.
  • On Thursday, June 1st, Bioventures Ltd Novartis sold 46,261 shares of Ra Pharmctl stock. The shares were sold at an average price of $23.93, for a total value of $1,107,025.73.
  • On Friday, May 26th, Bioventures Ltd Novartis sold 5,353 shares of Ra Pharmctl stock. The shares were sold at an average price of $25.14, for a total value of $134,574.42.
  • On Wednesday, May 24th, Bioventures Ltd Novartis sold 17,451 shares of Ra Pharmctl stock. The shares were sold at an average price of $25.01, for a total value of $436,449.51.
  • On Thursday, May 18th, Bioventures Ltd Novartis sold 9,019 shares of Ra Pharmctl stock. The shares were sold at an average price of $25.50, for a total value of $229,984.50.
  • On Wednesday, May 17th, Bioventures Ltd Novartis sold 42,615 shares of Ra Pharmctl stock. The shares were sold at an average price of $25.90, for a total value of $1,103,728.50.

Ra Pharmctl Inc (NASDAQ RARX) traded down 0.28% during trading on Friday, reaching $21.30. The company had a trading volume of 179,542 shares. The stock has a 50 day moving average price of $23.17 and a 200-day moving average price of $19.70. Ra Pharmctl Inc has a 52-week low of $12.05 and a 52-week high of $27.84. The company’s market capitalization is $480.68 million.

Ra Pharmctl (NASDAQ:RARX) last announced its quarterly earnings data on Thursday, May 11th. The company reported ($0.50) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.58) by $0.08. On average, equities research analysts anticipate that Ra Pharmctl Inc will post ($2.08) earnings per share for the current fiscal year.

Insider Buying and Selling by Quarter for Ra Pharmctl (NASDAQ:RARX)

ILLEGAL ACTIVITY WARNING: “Bioventures Ltd Novartis Sells 12,114 Shares of Ra Pharmctl Inc (RARX) Stock” was first reported by Chaffey Breeze and is owned by of Chaffey Breeze. If you are reading this news story on another site, it was copied illegally and republished in violation of United States & international copyright and trademark law. The correct version of this news story can be viewed at https://www.chaffeybreeze.com/2017/06/16/ra-pharmaceuticals-inc-rarx-major-shareholder-bioventures-ltd-novartis-sells-12114-shares-updated.html.

Several large investors have recently made changes to their positions in the stock. Novo A S acquired a new stake in shares of Ra Pharmctl during the fourth quarter worth $30,859,000. Acuta Capital Partners LLC acquired a new stake in shares of Ra Pharmctl during the fourth quarter worth $5,740,000. Franklin Resources Inc. acquired a new stake in shares of Ra Pharmctl during the fourth quarter worth $5,560,000. Deerfield Management Co. acquired a new stake in shares of Ra Pharmctl during the fourth quarter worth $4,916,000. Finally, VHCP Management II LLC increased its stake in shares of Ra Pharmctl by 33.6% in the first quarter. VHCP Management II LLC now owns 725,029 shares of the company’s stock worth $15,436,000 after buying an additional 182,529 shares in the last quarter. 62.85% of the stock is owned by institutional investors and hedge funds.

RARX has been the topic of several recent analyst reports. BMO Capital Markets increased their target price on Ra Pharmctl from $24.00 to $31.00 and gave the company a “positive” rating in a report on Tuesday, March 7th. Jefferies Group LLC reissued a “buy” rating and issued a $25.00 target price on shares of Ra Pharmctl in a report on Wednesday, April 26th. Zacks Investment Research lowered Ra Pharmctl from a “hold” rating to a “sell” rating in a report on Friday, March 10th. Finally, Credit Suisse Group reissued an “outperform” rating and issued a $19.00 target price on shares of Ra Pharmctl in a report on Tuesday, April 18th. Five analysts have rated the stock with a buy rating, Ra Pharmctl currently has an average rating of “Buy” and an average target price of $27.00.

About Ra Pharmctl

Ra Pharmaceuticals, Inc is a United States-based clinical-stage biopharmaceutical company. The Company focuses on the development of therapeutics for diseases of complement dysregulation and a range of orphan indications. It utilizes small molecules and peptide approaches to address pathological targets in the complement cascade.

Receive News & Ratings for Ra Pharmctl Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ra Pharmctl Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply